ReviewMicroorganisms2019
Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity.
Review in Microorganisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Efficiency of nanovaccines compared with antibiotic therapy in the prevention and immunomodulation of listeriosis.Emerging microbes & infections · 2026Article
- Preclinical Evaluation of a Microneedle-Delivered Adjuvanted Microparticulate Gonorrhea Vaccine in Non-Human Primates.Vaccines · 2026Article
- Article
- Antibody response induced by structural proteins fromFrontiers in microbiology · 2026Article
- Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant.ImmunoHorizons · 2025Article
- Review
- The BCG vaccine, advantages, and disadvantages of introducing new generation vaccines againstClinical and experimental vaccine research · 2024Review
- Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal.Heliyon · 2024Review
- Importance of adjuvant selection in tuberculosis vaccine development: Exploring basic mechanisms and clinical implications.Vaccine: X · 2023Review
- Review
- Mucosal and systemic immunization against tuberculosis by ISCOMATRIX nano adjuvant co-administered with alginate coated chitosan nanoparticles.Iranian journal of basic medical sciences · 2023Article
- Evaluation of the immunotoxicity and allergenicity of a new intranasal influenza vector vaccine against tuberculosis carrying TB10.4 and HspX antigens.Iranian journal of basic medical sciences · 2023Article
- Intranasal bovine β-defensin-5 enhances antituberculosis immunity in a mouse model by a novel protein-based respiratory mucosal vaccine.Virulence · 2022Article
- Formulated Phospholipids as Non-Canonical TLR4 Agonists.Pharmaceutics · 2022Article
- Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice.Microorganisms · 2022Article
- Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity.Microorganisms · 2022Article
- Virulence Mechanisms ofFrontiers in microbiology · 2022Review
- Article
- Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection.mBio · 2021Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Tuberculosis (TB) caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.